Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing ...

HOMA-IR z-scores were associated with increased risks for incident lung disease, interstitial lung abnormalities, and ...

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...

Tuberculosis remains a public health crisis. The World Health Organization's Global Tuberculosis Report released in November ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR) and non-invasive variables were examined against early (within 12 months) and overall mortality. A priori thresholds were ...

After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...

Increasing average concentrations of sotatercept improved 6-minute walk distance, pulmonary vascular resistance, and levels ...

Our trail columnist wrecked his feet on a thru-hike. Then he tried toe spacers to fix his foot pain, and never travels ...

In patients with familial PAH, SMAD5 appears to be a novel gene that warrants consideration for genetic testing, according to ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

In most cases, leftover pathology samples are thrown away. Sometimes though, they may be used again for other purposes, ...